Male Health Drug Development Pipeline Review, 2017

  • ID: 4410324
  • Report
  • 125 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Biolab Farmaceutica Ltda
  • GL Pharm Tech Corp
  • MEI Pharma Inc
  • NAL Pharmaceuticals Ltd
  • SK Chemicals Co Ltd
  • MORE

Summary

Male hypogonadism is characterized by androgen deficiency and infertility. Hypogonadism can be caused by disorders at the hypothalamic or pituitary level (hypogonadotropic forms) or by testicular dysfunction (hypergonadotropic forms). There are a total of 23 products in development for this indication, by 19 companies and one academic institution. Key companies operating in this pipeline space include Lipocine, M et P Pharma, Repros Therapeutics and TesoRx Pharma.

Erectile dysfunction is defined as the inability to achieve and maintain an erection sufficient to permit satisfactory intercourse. There are a total of 36 products in development for this indication, by 31 companies and two academic institutions. Key companies operating in this pipeline space include Mitsubishi Tanabe Pharma, Futura Medical, Monosol Rx and NAL Pharmaceuticals.

Finally, Benign prostatic hyperplasia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 29 products in development for this indication, by 26 companies and four academic institutions. Key companies operating in this pipeline space include Chong Kun Dang Pharmaceutical, Nymox Pharmaceutical and Yungjin Pharm.

The most common target for male hypogonadism is the androgen receptor, while phosphodiesterase 5 targets dominate the erectile dysfunction pipeline. Targets for the treatment of benign prostatic hyperplasia are more diverse with a strong presence of both androgen receptor and phosphodiesterase targets.

The report, "Male Health Drug Development Pipeline Review, 2017" provides an overview of the male health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Male Hypogonadism, Erectile Dysfunction and Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for male health therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of male health?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Biolab Farmaceutica Ltda
  • GL Pharm Tech Corp
  • MEI Pharma Inc
  • NAL Pharmaceuticals Ltd
  • SK Chemicals Co Ltd
  • MORE

1 Table of Contents

2 Introduction
2.1 Male Health Report Coverage
2.2 Male Hypogonadism - Overview
2.3 Erectile Dysfunction - Overview
2.4 Benign Prostatic Hyperplasia - Overview

3 Therapeutics Development
3.1 Male Hypogonadism
3.2 Erectile Dysfunction
3.3 Benign Prostatic Hyperplasia

4 Therapeutics Assessment
4.1 Male Hypogonadism
4.2 Erectile Dysfunction
4.3 Benign Prostatic Hyperplasia

5 Companies Involved in Therapeutics Development
5.1 Male Hypogonadism
5.2 Erectile Dysfunction
5.3 Benign Prostatic Hyperplasia

6 Dormant Projects
6.1 Male Hypogonadism
6.2 Erectile Dysfunction
6.3 Benign Prostatic Hyperplasia

7 Discontinued Products
7.1 Male Hypogonadism
7.2 Erectile Dysfunction
7.3 Benign Prostatic Hyperplasia

8 Product Development Milestones
8.1 Male Hypogonadism
8.2 Erectile Dysfunction
8.3 Benign Prostatic Hyperplasia

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation

List of Tables
Table 1: Number of Products under Development for Male Hypogonadism, H2 2017
Table 2: Number of Products under Development by Companies, H2 2017
Table 3: Number of Products under Development by Universities/Institutes, H2 2017
Table 4: Products under Development by Companies, H2 2017
Table 5: Products under Development by Universities/Institutes, H2 2017
Table 6: Number of Products under Development for Erectile Dysfunction, H2 2017
Table 7: Number of Products under Development by Companies, H2 2017
Table 8: Number of Products under Development by Universities/Institutes, H2 2017
Table 9: Products under Development by Companies, H2 2017
Table 10: Products under Development by Universities/Institutes, H2 2017
Table 11: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017
Table 12: Number of Products under Development by Companies, H2 2017
Table 13: Number of Products under Development by Universities/Institutes, H2 2017
Table 14: Products under Development by Companies, H2 2017
Table 15: Products under Development by Universities/Institutes, H2 2017
Table 16: Number of Products by Stage and Target, H2 2017
Table 17: Number of Products by Stage and Mechanism of Action, H2 2017
Table 18: Number of Products by Stage and Route of Administration, H2 2017
Table 19: Number of Products by Stage and Molecule Type, H2 2017
Table 20: Number of Products by Stage and Target, H2 2017
Table 21: Number of Products by Stage and Mechanism of Action, H2 2017
Table 22: Number of Products by Stage and Route of Administration, H2 2017
Table 23: Number of Products by Stage and Molecule Type, H2 2017
Table 24: Number of Products by Stage and Target, H2 2017
Table 25: Number of Products by Stage and Mechanism of Action, H2 2017
Table 26: Number of Products by Stage and Route of Administration, H2 2017
Table 27: Number of Products by Stage and Molecule Type, H2 2017
Table 28: Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2017
Table 29: Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2017
Table 30: Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2017
Table 31: Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2017
Table 32: Male Hypogonadism - Pipeline by Lipocine Inc, H2 2017
Table 33: Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2017
Table 34: Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2017
Table 35: Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2017
Table 36: Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2017
Table 37: Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2017
Table 38: Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2017
Table 39: Male Hypogonadism - Pipeline by The Female Health Company, H2 2017
Table 40: Male Hypogonadism - Pipeline by Viramal Ltd, H2 2017
Table 41: Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2017
Table 42: Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2017
Table 43: Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H2 2017
Table 44: Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2017
Table 45: Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Table 46: Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017
Table 47: Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2017
Table 48: Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Table 49: Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2017
Table 50: Erectile Dysfunction - Pipeline by IntelGenx Corp, H2 2017
Table 51: Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H2 2017
Table 52: Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H2 2017
Table 53: Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2017
Table 54: Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Table 55: Erectile Dysfunction - Pipeline by Monosol Rx LLC, H2 2017
Table 56: Erectile Dysfunction - Pipeline by N4 Pharma Plc, H2 2017
Table 57: Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
Table 58: Erectile Dysfunction - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017
Table 59: Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H2 2017
Table 60: Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2017
Table 61: Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H2 2017
Table 62: Erectile Dysfunction - Pipeline by Suda Ltd, H2 2017
Table 63: Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
Table 64: Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2017
Table 65: Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H2 2017
Table 66: Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2017
Table 67: Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H2 2017
Table 68: Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H2 2017
Table 69: Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H2 2017
Table 70: Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2017
Table 71: Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Table 72: Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2017
Table 73: Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017
Table 74: Benign Prostatic Hyperplasia - Pipeline by GL Pharm Tech Corp, H2 2017
Table 75: Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017
Table 76: Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
Table 77: Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H2 2017
Table 78: Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
Table 79: Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H2 2017
Table 80: Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H2 2017
Table 81: Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Table 82: Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H2 2017
Table 83: Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H2 2017
Table 84: Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H2 2017
Table 85: Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Table 86: Benign Prostatic Hyperplasia - Pipeline by The Female Health Company, H2 2017
Table 87: Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
Table 88: Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Co Ltd, H2 2017
Table 89: Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H2 2017
Table 90: Male Hypogonadism - Dormant Projects, H2 2017
Table 91: Erectile Dysfunction - Dormant Projects, H2 2017
Table 92: Benign Prostatic Hyperplasia - Dormant Projects, H2 2017
Table 93: Male Hypogonadism - Discontinued Products, H2 2017
Table 94: Erectile Dysfunction - Discontinued Products, H2 2017
Table 95: Benign Prostatic Hyperplasia - Discontinued Products, H2 2017

List of Figures
Figure 1: Number of Products under Development for Male Hypogonadism, H2 2017
Figure 2: Number of Products under Development by Companies, H2 2017
Figure 3: Number of Products under Development for Erectile Dysfunction, H2 2017
Figure 4: Number of Products under Development by Companies, H2 2017
Figure 5: Number of Products under Development by Universities/Institutes, H2 2017
Figure 6: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017
Figure 7: Number of Products under Development by Companies, H2 2017
Figure 8: Number of Products under Development by Universities/Institutes, H2 2017
Figure 9: Number of Products by Targets, H2 2017
Figure 10: Number of Products by Stage and Targets, H2 2017
Figure 11: Number of Products by Mechanism of Actions, H2 2017
Figure 12: Number of Products by Stage and Mechanism of Actions, H2 2017
Figure 13: Number of Products by Routes of Administration, H2 2017
Figure 14: Number of Products by Stage and Routes of Administration, H2 2017
Figure 15: Number of Products by Molecule Types, H2 2017
Figure 16: Number of Products by Stage and Molecule Types, H2 2017
Figure 17: Number of Products by Top 10 Targets, H2 2017
Figure 18: Number of Products by Stage and Top 10 Targets, H2 2017
Figure 19: Number of Products by Top 10 Mechanism of Actions, H2 2017
Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Figure 21: Number of Products by Routes of Administration, H2 2017
Figure 22: Number of Products by Stage and Routes of Administration, H2 2017
Figure 23: Number of Products by Molecule Types, H2 2017
Figure 24: Number of Products by Stage and Molecule Types, H2 2017
Figure 25: Number of Products by Top 10 Targets, H2 2017
Figure 26: Number of Products by Stage and Top 10 Targets, H2 2017
Figure 27: Number of Products by Top 10 Mechanism of Actions, H2 2017
Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Figure 29: Number of Products by Routes of Administration, H2 2017
Figure 30: Number of Products by Stage and Routes of Administration, H2 2017
Figure 31: Number of Products by Molecule Types, H2 2017
Figure 32: Number of Products by Stage and Molecule Types, H2 2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addex Therapeutics Ltd
  • AndroScience Corp
  • Antares Pharma Inc
  • Aphios Corp
  • Apricus Biosciences Inc
  • Astellas Pharma Inc
  • BCWorld Pharm Co Ltd
  • Biolab Farmaceutica Ltda
  • Biopharm GmbH
  • Can-Fite BioPharma Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Clarus Therapeutics Inc
  • Curadis GmbH
  • Dongkook Pharmaceutical Co Ltd
  • EndoCeutics Inc
  • Fabre-Kramer Pharmaceuticals Inc
  • Ferring International Center SA
  • Futura Medical Plc
  • GL Pharm Tech Corp
  • Hanmi Pharmaceuticals Co Ltd
  • Health Ever Bio-Tech Co Ltd
  • Humanetics Corp
  • IntelGenx Corp
  • Ion Channel Innovations LLC
  • iX Biopharma Ltd
  • Jeil Pharmaceutical Co Ltd
  • Lipocine Inc
  • M et P Pharma AG
  • MEI Pharma Inc
  • Medlab Clinical Ltd
  • Meiji Seika Pharma Co Ltd
  • Merck & Co Inc
  • Mereo Biopharma Group Plc
  • Mezzion Pharma Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Monosol Rx LLC
  • N4 Pharma Plc
  • NAL Pharmaceuticals Ltd
  • Nanoform Cardiovascular Therapeutics Ltd
  • Nymox Pharmaceutical Corp
  • OPKO Health Inc
  • Ono Pharmaceutical Co Ltd
  • Palatin Technologies Inc
  • Pharmicell Co Ltd
  • Repros Therapeutics Inc
  • SK Chemicals Co Ltd
  • Sophiris Bio Inc
  • Suda Ltd
  • Sun Pharma Advanced Research Company Ltd
  • TesoRx Pharma LLC
  • The Female Health Company
  • Viramal Ltd
  • XuanZhu Pharma Co Ltd
  • Yangtze River Pharmaceutical Group
  • Yungjin Pharm Co Ltd
  • Yuyu Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll